The portfolio of the Rus Biopharm group of companies has been replenished with another socially significant medicinal product included in the list of VED. The Ministry of Health of the Russian Federation has registered the drug "Insudive" (INN — semaglutide), a solution for subcutaneous administration in three dosages: 0.25 mg/dose; 0.5 mg/dose; 1 mg/dose[1].
This drug is a complete analogue of the original Ozempik drug produced by Novo Nordisk A/S, which in the fall of 2022 notified Roszdravnadzor of the cessation of production and supply of the drug to the Russian market[2].
"Insudive" is used in the fields of endocrinology and cardiology, it is prescribed to adult patients with type 2 diabetes mellitus to improve sugar control in the body. The drug can be used both as monotherapy and in complex therapy in combination with other means to control sugar content. As an adjunct to standard treatment, Insudive reduces the risk and prevents serious complications from the cardiovascular system in patients with type 2 diabetes mellitus and high cardiovascular risk.
Diabetes is a chronic endocrine disorder. In type 1 diabetes, the pancreas does not produce enough insulin. With type 2 diabetes, the body cannot effectively use insulin. If left untreated, type 2 diabetes can lead to high blood sugar levels, which harms the nervous system and blood vessels. According to WHO, the risk factors for the disease include overweight, insufficient physical activity and genetic factors. More than 95% of all diabetics suffer from type 2 diabetes[3].
This drug is a prescription drug, it should be taken only after consultation with a doctor and according to his prescription.
[1] Registration certificate // State Register of Medicines. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c0b119b3-2f9e-4b68-9129-dab612dde29f (date of access: 07/19/2024).
[2] Novo Nordisk has notified the termination of Ozempika supplies to Russia // RBC. URL: https://www.rbc.ru/society/25/03/2023/641b172b9a79471091927566 (date of access: 07/19/2024).
[3] Diabetes // World Health Organization. URL: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes (date of request: 07/23/2024).